COST OF ILLNESS PADA PASIEN PENYAKIT KANKER PAYUDARA DI RSUD ULIN BANJARMASIN

2020 ◽  
Vol 5 (2) ◽  
pp. 407-415
Author(s):  
Noor Aisyah ◽  
◽  
Shela Puji Dina
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cost Of Illness ◽  
Medical Cost ◽  
Indirect Costs ◽  
Medical Costs ◽  
Patient Treatment ◽  
Breast Cancer Patients ◽  
Economic Burden Of Disease ◽  
Direct Medical Costs

The cost of illness is an important element in disease decision making because it can evaluate the economic burden of disease. One of them is breast cancer because breast cancer is a catastrophic disease. This study aims to determine direct medical costs, direct non-medical costs, indirect costs, and total costs based on a societal perspective in breast cancer patients at Ulin Hospital, Banjarmasin. This study is an observational analytic study with a prevalence-based cost of illness approach. Data was taken retrospectively for direct medical costs collected from patient medical records that met the inclusion and exclusion criteria, patient treatment data, and details of direct medical costs for the period January-July 2020. Direct non-medical costs and indirect costs were taken from the results of filling out a questionnaire to Breast cancer patients who have undergone treatment in the inpatient room of RSUD Ulin Banjarmasin. Data analysis used descriptive statistics to identify patient characteristics and the costs of breast cancer. The results of the study, the average direct medical cost of breast cancer patients at Ulin Banjarmasin Hospital was Rp. 6,281,700. The average direct non-medical cost was Rp. 416,780 and the average indirect cost was Rp. 229,820. Meanwhile, the average overall cost per episode of inpatient was Rp. 6,928,300

Developing National Estimates of the Out-of-Pocket Costs of Cancer: The Importance of Including Patients with Lymphoma.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3138-3138
Author(s):  
Kathryn R. McCaffrey ◽  
Kenneth R. Carson ◽  
Lucie Kutikova ◽  
Matt Fisher ◽  
Simon Pickard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Medical Care ◽  
Direct Medical Cost ◽  
Cancer Patients ◽  
Medical Cost ◽  
Medical Costs ◽  
Breast Cancer Patients ◽  
Direct Medical Costs ◽  
12Th Grade ◽  
Out Of Pocket Costs

Abstract Background: While Congress has mandated that the NIH provide a national estimate of the cost of cancer, almost all cancer cost studies have focused exclusively on breast cancer. No study has reported comparison data for persons with Hodgkin’s disease (HD) or non-Hodgkin’s lymphoma (NHL). These illnesses have a high cure rate, and affected persons are likely to experience significant economic hardships. Many participate in the workforce during treatment and long after the treatment is complete. Herein, we report preliminary results from an ongoing study on the out-of-pocket direct medical and non-medical costs for a cohort of patients with lymphoma and provide contextual comparison with a cohort of breast cancer patients who received care at the same cancer center (Arozullah, Supportive Oncology, 2004). Methods: 178 breast cancer and lymphoma patients provided information on out-of-pocket costs for the preceding 3-month period; 12% had a diagnosis of HD or NHL. In total, 120 lymphoma patients will be interviewed for this study. Direct medical costs are costs related to medical care such as medications, procedures, and doctor visits. Direct non-medical costs are costs related to cancer, but not medical care, such as costs for meals, transportation, parking, and phone calls. Results: The majority of both lymphoma and breast cancer patients were < 65 years old, married, and employed. All patients had healthcare insurance coverage, with the majority insured with private plans. In comparison to women with breast cancer, persons with HD/NHL had similar mean monthly out-of-pocket cost expenditures, $635 versus $728. For lymphoma patients, factors associated with high direct medical costs included ≤ 12th grade education ($1,585/month) and HD ($1,133/month). Conclusion: Mean monthly out-of-pocket expenditures are similar for HD/NHL and breast cancer. Direct medical out-of-pocket expenditures for lymphoma vary. Direct medical expenditures are greatest for HD ($1,130), intermediate for aggressive NHL and breast cancer ($512–$597), and lowest for indolent NHL ($180). Comprehensive economic analyses of cancer should include a range of malignancies. Average Monthly Out-of-Pocket Costs for Lymphoma and Breast Cancer Patients. Direct Medical Cost Direct Medical Cost Direct Non-Medical Cost Direct Non-Medical Cost Lymphoma Breast Lymphoma Breast Household Income < $60,000 $381 $664 $40 $111 ≥ $60,000 $599 $553 $159 $161 Education ≤ 12th grade $1,585 $610 $72 $118 > 12th grade $437 $653 $141 $122 Diagnosis < 6 Months $577 $487 $114 $135 ≥ 6 Months $333 $660 $128 $130 Total Lymphoma $516 .. $119 .. HD $1,133 .. $155 .. AggressiveNHL $512 .. $167 .. Indolent NHL $180 .. $166 .. Total Breast Cancer .. $597 .. $131

scholarly journals Economic Burden of Tuberculosis Diabetes Co-Morbidity in Tuberculosis Patients Attending Two Chest Clinics in Lagos State

2021 ◽  
Vol 16 (2) ◽  
pp. 91-100
Author(s):  
F.A. Ayeni ◽  
O.O. Oyetunde ◽  
B.A. Aina ◽  
H.O. Yarah
Keyword(s):  
Direct Medical Cost ◽  
Medical Cost ◽  
Indirect Costs ◽  
Medical Costs ◽  
Female Patients ◽  
Direct Medical Costs ◽  
Tb Treatment ◽  
Co Morbidity ◽  
Lagos State ◽  
Significant Burden

Background: Diabetes mellitus (DM) increases the risk of developing tuberculosis (TB) three-fold. The cost of accessing care for TB-DM co-morbidity poses a significant burden on patients, as they bear both direct and indirect costs of treatment, mostly of out-of-pocket.Objective: To estimate the direct medical cost of illness in patients with TB-DM co-morbidity in two chest clinics in Lagos State.Materials and Methods: An observational study, carried out in two chest clinics in Lagos State to evaluate direct medical costs associated with TBDM co-morbidity during TB treatment. A semi structured questionnaire, pharmacy price list of drugs and an online transportation service lara.ng was employed to document and quantify prescribed medications, laboratory investigations, number of clinic attendance and attendant transportation costs.Results: Among the participants, 53.8% were females. The mean age was 50.7±9.7 years. The total direct medical and non-medical costs for TBDM management was NGN8,604,819 (USD24,585.20) for the duration of TB treatment. Average cost per patient (CPP) was NGN179,384.85 (USD512.53). This was equivalent to 49.8% of the current national minimum wage. Male patients incurred more mean direct medical cost than female patients (NGN26, 647.90 vs NGN24, 020.40), while female patients incurred more mean direct non-medical costs than the males (NGN22, 314.30 versus NGN13, 041.70). Patients aged 60 years and above incurred the highest mean direct costs compared to other age groups.Conclusion: Direct medical costs are substantial in TBDM co-morbidity and increase with age.

Abstract 19839: Clinical and Economic Burden of Rheumatic Heart Disease in Low-Income Nations: Estimating the Cost-of-Illness in India and Uganda

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Alexander T Sandhu ◽  
Kathikeyan G ◽  
Ann Bolger ◽  
Emmy Okello ◽  
Dhruv S Kazi
Keyword(s):  
Heart Disease ◽  
Rheumatic Heart Disease ◽  
Cost Of Illness ◽  
Economic Burden ◽  
Indirect Costs ◽  
Medical Costs ◽  
Discrete State ◽  
Direct Medical Costs ◽  
The Cost ◽  
Rheumatic Heart

Introduction: Rheumatic heart disease (RHD) strikes young adults at their peak economic productivity. Defining the global economic burden of RHD may motivate investments in research and prevention, yet prior approaches considering only medical costs may have underestimated the cost of illness. Objectives: To estimate the clinical and economic burden of RHD in India and Uganda. Outcomes were disability-adjusted life years (DALYs), direct medical costs, and indirect costs due to disability and premature mortality (2012 USD). Methods: We used a discrete-state Markov model to simulate the natural history of RHD using country-, age-, and gender-specific estimates from the literature and census data. We estimated direct medical costs from WHO-CHOICE and Disease Control and Prevention 3 publications. We conservatively estimated indirect costs (lost earnings and imputed caregiver costs) from World Bank data using novel economic methods. Results: In 2012, RHD generated 6.1 million DALYs in India and cost USD 10.7 billion (Table 1), including 1.8 billion in direct medical costs and 8.9 billion in indirect costs. During the same period, RHD produced 216,000 DALYs in Uganda, and cost USD 414 million, and, as in India, indirect costs represented the majority (88%) of the cost of illness. In both countries, women accounted for the majority (71-80%) of the DALYs; in Uganda, women bore 75% of the total cost. In sensitivity analyses, higher progression rates for subclinical disease doubled direct costs and DALYs. Conclusion: RHD exacts an enormous toll on the populations of India and Uganda, and its economic burden may be grossly underestimated if indirect costs are not systematically included. Women bear a disproportionate clinical burden from pregnancy-related complications. These results suggest that effective prevention and screening of RHD may represent a sound public health investment, particularly if targeted at high-risk subgroups such as young women.

Would women with breast cancer prefer to receive an antidepressant for anxiety or depression from their oncologist?

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 219-219
Author(s):  
Daniel Curtis McFarland ◽  
Megan Johnson Shen ◽  
Kirk Harris ◽  
Amy Tiersten ◽  
John Mandeli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mental Health ◽  
Health Professional ◽  
Cancer Patients ◽  
Mental Health Professional ◽  
Depression Scale ◽  
Patient Treatment ◽  
Anxiety And Depression ◽  
Breast Cancer Patients ◽  
To Receive

219 Background: Patient treatment preferences for the management of anxiety and depression influence adherence and treatment outcomes, yet breast cancer patient preferences for provider-specific pharmacologic management of anxiety and depression is unknown. This study examined breast cancer patients’ antidepressant prescriber preferences and their preferences for treatment by a mental health professional. Methods: Breast cancer patients (Stage 0-IV) were asked two questions: 1) “Would you be willing to have your oncologist treat your depression or anxiety with an antidepressant medication if you were to become depressed or anxious at any point during your treatment?”; and 2) “Would you prefer to be treated by a psychiatrist or mental health professional for problems with either anxiety or depression?” Additionally, the Distress Thermometer and Problem List, Hospital Anxiety and Depression Scale, Risky Families Questionnaire, and demographic information were assessed. Results: One hundred twenty-five participants completed the study. 60.4% were willing to accept an antidepressant from an oncologist and 26.3% preferred treatment by a mental health professional. 77.3% who were willing to receive an antidepressant from their oncologist reported either no preference or that treatment by a mental health professional didn’t matter (p = 0.01). Participants taking antidepressants (p = 0.02) or reporting high chronic stress (p = 0.03) preferred a mental health professional. Conclusions: The majority of patients accepted antidepressant prescribing by their oncologist; only a minority preferred treatment by a mental health professional. These findings suggest the benefit for promoting education of oncologists to assess psychological symptoms and manage anxiety and depression as a routine part of an outpatient visit.

scholarly journals PCN128 EFFECTS AND MEDICAL COSTS OF A STRUCTURED PSYCHOSOCIAL GROUP INTERVENTION FOR BREAST CANCER PATIENTS AFTER SURGERY

2010 ◽  
Vol 13 (7) ◽  
pp. A276
Author(s):  
K Shimozuma ◽  
T Shiroiwa ◽  
Y Sagara ◽  
R Tobata ◽  
H Ueo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Group Intervention ◽  
Medical Costs ◽  
Breast Cancer Patients

scholarly journals Indirect Costs Among Metastatic Breast Cancer Patients Receiving Eribulin

2015 ◽  
Vol 18 (3) ◽  
pp. A202 ◽  
Author(s):  
Y. Wan ◽  
R. Copher ◽  
S. Corman ◽  
S. Abouzaid ◽  
X. Gao
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Indirect Costs ◽  
Breast Cancer Patients

scholarly journals Cost of illness of type 2 diabetes mellitus from the patient’s perspective: a study from several primary healthcare centres and a hospital in Yogyakarta, Indonesia

2020 ◽  
Vol 11 (4) ◽  
pp. 7442-7453
Author(s):  
Dwi Endarti ◽  
Anna Wahyuni Widayanti ◽  
Ehga Ayodya Rahmawati ◽  
Nellatul Khaher ◽  
Siti Rahayu
Keyword(s):  
Diabetes Mellitus ◽  
Cost Of Illness ◽  
Medical Cost ◽  
Primary Healthcare ◽  
Indirect Costs ◽  
Medical Costs ◽  
Health Facilities ◽  
Major Health Problem ◽  
Illness Study ◽  
Secondary Hospital

Diabetes mellitus is a major health problem that had a consequence of high cost related to treatment and disease impact. This study aimed to estimate the cost of illness related T2DM from the perspective of patients. This study applied a prevalence-based cost of illness study from the perspective of patients. Data of direct medical costs, direct non-medical costs and indirect costs were collected by interviewing patients. The study involved patients covered by the national health insurance scheme as study respondents, which consisted of 96 patients visiting three public primary healthcare centres and 35 patients visiting a private secondary hospital in Yogyakarta Province, Indonesia. From the perspective of patients in Yogyakarta-Indonesia, the total cost of illness of T2DM within three months period was IDR 95,458 (USD 6.58) for patients at PHCs and IDR 340,159 (USD 23.46) for patients at the hospital, which were about 2% to 7% of the minimum wage rate. Indirect cost was the highest contribution of cost of illness (IDR 40,436/USD 2.79) to IDR 398,836/USD 17.63) and followed by direct medical cost (IDR 32,349/USD 2.23 to IDR 44,157/USD 3.05) and direct non-medical cost (IDR 22,673/USD 1.56 to IDR 40,334/USD 2.78). Cost of illness from out of pocket patients in this study was led by visits to other health facilities (the health facilities outside of study site) for obtaining health service related to T2DM disease. This study anticipated that T2DM had a consequence to out of the pocket cost of treatment and further productivity lost of patients and their caregivers.

Sign in / Sign up

Export Citation Format

Share Document